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“Pharmacologic reperfusion therapy with
indigenous tenecteplase in 15,222 patients with
ST elevation myocardial infarction e the Indian
registry” by Iyengar et alI read with great interest the article by Iyengar et al1
examining the efficacy and safety of indigenous tenecteplase
such as used in the real world in India. The figures reported
are impressive, with 15,222 consecutive patients included in
722 centers, as well as striking clinical results. I have, how-
ever, several comments and interrogations regarding the
study.
First, there is no mention of whether the patients were
asked to give informed consent for their participation in the
registry, and whether the study was approved by an ethics
committee.
Second, the population is described as a consecutive pop-
ulation of patients receiving indigenous tenecteplase; how
many patients admitted to the participating institutions dur-
ing the study period of recruitment did not get tenecteplase,
and what was their clinical profile in comparison with that of
the registry patients?
Third, the main efficacy criterion, clinically successful
thrombolysis, is of an extremely subjective nature: what is
“significant relief of chest pain” and “significant resolution of
ST-segment elevation”?Was chest pain quantified in anyway,
and was there any central reading of the ECGs? At what time
with respect to the time of administration of indigenous ten-
ecteplasewas clinical success assessed? (In the end chest pain
resolves in all AMI patients!). This question is central to the
interpretation of the results presented here, as this is a purely
observational study, where the subjective interpretation of
success by the participating clinicians is most likely to explain
the properly extraordinary success rate reported in the article.
It is somewhat surprising that the authors failed to report
initial TIMI flow of the culprit artery in the small proportion of
patients who underwent coronary angiography.
Fourth, the way the complication rates are presented for
subgroups is not proper: comparisons should not be made
with the rates observed in the overall population, as it con-
tains the subgroup of interest. The ways the results presented
here preclude any statistical analysis.Finally, the overall clinical complication rates observed are
most likely explained by the very young age of the population
(55 years on average, with 8% only aged >70 years). In such
young STEMI patients, 30-daymortality is extremely low, even
in the absence of any reperfusion therapy. In the FAST-MI 2010
registry,2 themortalityof patients less than70yearsof age (and
with an average age of 55 years) was 1.80% for those who
receivedno reperfusion therapy, comparedwith 0.4% for those
treatedwith fibrinolytic therapy (mainly original tenecteplase)
and 1.0% for those receiving primary PCI (personal data).
Because of all these limitations, strong conclusions such
as “this study establishes the efficacy of a thrombolytic like
TNK in prompt and effective reperfusion of the myocardium”
are inappropriate. Only specifically designed, randomized
controlled clinical trials can truly establish the efficacy of any
therapy. Observational data can only show associations and it
is essential that clinicians refrain from drawing hasty cau-
sality inferences from such data.3Disclosures
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[1] Thispublication isa compilationof observationsmadeby
physicians in treating their patients of ST Elevation
Myocardial Infarction (STEMI) with the indigenous ten-
ecteplase. It is a registry which is observational,
non-interventional and retrospective in nature. Patient
identity was not revealed. Hence there was no require-
ment for informedconsentor ethics committeeapproval.
[2] Records of patients who received the indigenous ten-
ecteplase only were compiled. Records of other patients
were not compiled or evaluated.
[3] Clinically successful thrombolysis was judged by (a).
Resolution of chest pain & (b) 50% ST segment resolu-
tion at 90 minutes. Pain relief assessment was subjec-
tive and was noted as Yes/No. No pain scale was used.
There was no central ECG monitoring.
The study did not look at the angiographic profile. However
a sub study is being planned to look into the angiographic
patency rates and TIMI flow.
[4] Analysiswas done comparing the overall groupwith the
high risk subgroups, as also between subgroups (elderly
vs nonelderly; diabetics vs nondiabetics; male vs
female) ref. Fig 4 in the article.1
[5] We fully agree with the author’s contention that the
young age of the populationmight have been responsible
for the low mortality figures. However, divergent data
(including time of presentation, delay of thrombolysis)
complicate the issue. In the Fibrinolytic Therapy Trialists
(FTT) collaborative group data,2 the overall 30-day mor-
tality in the age group less than 55 years was 4.6% in the
control group and 3.4% in the thrombolysed group.
The figures quoted by the corresponding author show
substantial relative risk reduction in young STEMI patients
who received reperfusion therapy. Indian patients are
known to get Acute Coronary Syndrome (ACS) at a younger
age than their western counterparts.Randomized Clinical Trials (RCT) is certainly the gold
standard in clinical trials. But observational registry data
reflect real life scenario. The debate of superiority of each is an
open and ongoing academic debate. We need to use the “reg-
istries to investigate the past and develop the future”.3 Well
designed post-marketing surveillance registries can be used to
prove safety and efficacy in a broad spectrum of patients.4
The whole purpose of this registry was to examine the ef-
ficacy and safety of a low cost indigenous tenecteplase in a
financially challenged heterogenous population of India.r e f e r e n c e s
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